CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Retrospective analysis supports erenumab in trigeminal neuralgia

27 April 2021 | News

Improved pain scores and mood have been reported by patients with trigeminal neuralgia (TN) who were treated with erenumab. Nine out of 10 patients diagnosed with TN and treated with erenumab for six months reported improvement in pain severity according to a numeric pain rating scale (NPRS) from 0 to 10, and in global mood.

Three patients reported resolution of anxiety, and/or depression. Side effects were minimal with three patients reporting constipation, injection site reactions or both.

The authors stress that this is class IV evidence but conclude that erenumab increased the probability of improved pain control in patients with medication resistant trigeminal neuralgia.

Reference

Parascandolo E, Levinson K, Rizzoli P, Sharon R. Efficacy of Erenumab in the Treatment of Trigeminal Neuralgia: A Retrospective Case Series. Neurol Clin Pract. Published online 1 Apr 2021

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |